GLG Partners LP trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 13.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,000 shares of the company’s stock after selling 7,000 shares during the quarter. GLG Partners LP’s holdings in Zoetis were worth $2,869,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. raised its stake in Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the period. Guardian Life Insurance Co. of America grew its position in Zoetis by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after acquiring an additional 13 shares during the period. Point72 Asia Hong Kong Ltd purchased a new stake in Zoetis during the first quarter valued at about $111,000. Harfst & Associates Inc. increased its stake in Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after acquiring an additional 260 shares during the last quarter. Finally, Almanack Investment Partners LLC. acquired a new stake in Zoetis during the second quarter worth about $119,000. Hedge funds and other institutional investors own 93.20% of the company’s stock.

Zoetis Inc. (NYSE ZTS) traded up 0.53% during mid-day trading on Monday, reaching $64.10. The company had a trading volume of 459,424 shares. The company’s 50 day moving average is $62.44 and its 200 day moving average is $59.64. The stock has a market capitalization of $31.35 billion, a price-to-earnings ratio of 36.24 and a beta of 1.02. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $65.83.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.53. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm posted $0.49 EPS. Equities analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current year.

Several equities analysts recently weighed in on ZTS shares. BMO Capital Markets lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and lifted their target price for the company from $64.00 to $65.00 in a report on Tuesday, June 13th. They noted that the move was a valuation call. Cowen and Company set a $70.00 price target on Zoetis and gave the company a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald set a $75.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Monday, August 14th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research note on Friday, July 21st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $62.00 target price on shares of Zoetis in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $65.76.

TRADEMARK VIOLATION NOTICE: “Zoetis Inc. (ZTS) Shares Sold by GLG Partners LP” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/zoetis-inc-zts-shares-sold-by-glg-partners-lp/1603357.html.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.